Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743025 · ClinicalTrials.gov registry record · Phase 4
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
A Phase 4 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT03743025 is a Phase 4 study that was terminated before completion, run by Emory University. The registered enrollment target is 28 participants.
The verdict
NCT03743025, a Phase 4 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period.
Interventions
- OTHER Saline Injection
- DRUG Dulaglutide Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2023-05-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03743025
The ClinicalTrials.gov registry entry for NCT03743025 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline Injection is the first listed.
NCT03743025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03743025 about?
NCT03743025 is a clinical study titled "Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients". This study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period.
What is the current status of trial NCT03743025?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2019-03-08. Estimated completion is 2023-05-02.
What interventions are being tested in trial NCT03743025?
The interventions under investigation include: Saline Injection (OTHER), Dulaglutide Injection (DRUG).
Who is sponsoring clinical trial NCT03743025?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.